Sun Pharmaceutical is India's largest pharmaceutical company, specializing in a wide range of generic and branded formulations globally. The company shows healthy earnings growth of 27.4% and maintains a strong presence in complex therapeutic areas like oncology and dermatology.
The company exhibits consistent revenue growth and a very low beta of 0.124, suggesting the stock is significantly less volatile than the broader market. Its expansion into high-margin specialty medicines in the US market provides a strong foundation for potential future profitability.
A relatively high Price-to-Earnings (PE) ratio of 37.95 indicates the stock may be priced expensively compared to historical averages. Additionally, the pharmaceutical sector faces constant risks from stringent international regulatory audits and potential pricing pressures in the generic drug market.
This stock is generally suitable for beginners seeking exposure to the healthcare sector due to its market leadership and low volatility. However, the low dividend yield of 0.84% means it is better suited for those looking for capital appreciation rather than regular passive income.
Sun Pharma is well-positioned for the long term as global healthcare demand rises and the company invests in its specialty pipeline. Investors should monitor the company's ability to maintain its high earnings growth rate and manage its debt levels over several years.
In the Futures and Options segment, Sun Pharma is often used by sophisticated traders for hedging due to its low beta and high liquidity. Beginners should avoid F&O entirely, as these are high-risk derivative instruments that can lead to rapid capital loss compared to simple stock investing.
Headlines from across the web, sentiment-scored by AI.
# India stocks lower at close of trade; Nifty 50 down 0.32% Meanwhile, Eternal Ltd ([NSE:ETEA](https://www.investing.com/equities/zomato)) added 1.60% or 5.05 points to end at 320.95 and Sun Pharmaceutical Industries Ltd. ([NSE:SUN](https://www.investing.com/equities/sun-pharma-advanced-research)) was up 1.27% or 23.80 points to 1,898.90 in late trade.
It looks like Procter & Gamble Health Limited ( NSE:PGHL ) is about to go ex-dividend in the next three days. The...
# Sun Pharma seeks shareholder approval for promoter group reclassification ## Rationale and Governance | 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years | |-|-|-|-|-|-| | +0.63% | +2.50% | -0.98% | +8.94% | +16.01% | +149.92% | # Sun Pharma to host analyst meet in Mumbai on Sept 1 ## More News on Sun Pharmaceutical [view all](https://scanx.trade/stock-news/sun-pharmaceutical-ltd) [\ \ Sun Pharma gets NSE, BSE nod to reclassify Valia family as public shareholders Aug 06, 2026](https://scanx.trade/stock-market-news/companies/sun-pharma-gets-nse-bse-nod-to-reclassify-valia-family-as-public-shareholders/47584634)  Sun Pharmaceutical Industries Records ₹28.32 Crore Block Trade on NSE at ₹1957.50 Per Share Aug 03, 2026  Sun Pharmaceutical Industries Records ₹43.93 Crore Block Trade on NSE at ₹1964.40 Per Share Aug 03, 2026 ## Stocks ### Get More Market Insights with [Sun Pharmaceutical ](https://scanx.trade/company/sun-pharmaceutical-ltd)
Reported Consolidated quarterly numbers for Sun Pharma Advanced Research Company are: Net Sales at Rs 39.92 crore in June 2026 up 314.11% from Rs. 9.64...
Data as on March 2026. Individual Stock Breakdown. 1. Abbott India Ltd. Abbott India is one of those names that instantly commands respect in the pharma...
Sunshine Pictures IPO listed at a premium on NSE and BSE but fell short of grey-market expectations. Read about listing gains, GMP, subscription,...
In April 2024, InvestingPro's Fair Value models identified Sun Pharma Advanced Research Company Limited (NSE:SPRC) as significantly overvalued,...
Sun Pharma to hold investor meet on September 1, 2026. Event is part of Ashwamedh – Elara India Dialogue 2026. Meeting will be physical in Mumbai with group...